© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
The story of DOTAP Mesylate Salt reflects the evolution of gene delivery systems over the last few decades. Back in the late 20th century, gene therapy started as little more than an idea, chased by a handful of laboratories that dared to dream beyond classical drug development. Early approaches often hit a wall with viruses causing immune reactions or slipping off-target, which drove scientists to explore synthetic lipid-based delivery. DOTAP, or 1,2-dioleoyl-3-trimethylammonium-propane, came out of this search for safer carriers. It’s no stretch to say DOTAP’s appearance at the bench changed the tone in drug delivery meetings—suddenly, there was a tool that could pack genetic instructions into neat, protective lipid particles and ferry them safely across cell membranes, opening new options for every lab working on RNA, DNA, or CRISPR payloads.
DOTAP Mesylate Salt stands among the most popular cationic lipids in research today. What sets it apart is its ability to easily interact with negatively charged genetic materials like DNA and RNA, forming complexes that cells eagerly import. In practical terms, DOTAP forms the backbone of many lipid nanoparticle formulations, powering both research-grade and cutting-edge clinical delivery systems. I’ve noticed that, whether at university research centers or biotech companies, teams regularly turn to DOTAP when grappling with tricky transfection protocols. Its accessibility, paired with well-characterized behavior in both labs and literature, has earned DOTAP a solid reputation—especially given how it consistently outperforms many ancient reagents for transfection.
DOTAP Mesylate Salt displays a clear white to off-white powder in its pure form, and its tangible properties have practical implications. Its quaternary ammonium headgroup gives it a strong positive charge. This specific quaternary ammonium group binds tightly with negatively charged phosphate groups in nucleic acids. Chemically, DOTAP contains two unsaturated C18 oleoyl chains—a structure that boosts fluidity and fusion with cell membranes. That same feature allows it to integrate smoothly into lipid bilayers, which translates to faster, more reliable delivery. Its melting point and solubility often come up in the context of formulation chemistry, especially as folks experiment with combinations to raise stability or tweak performance.
Turning to technical documentation and labels, it’s common to see precise breakdowns of purity, counterion content, and residual solvent levels because small differences really show up in transfection results. DOTAP Mesylate’s purity usually exceeds 98 percent, which cuts down on unwanted reactions or byproducts. The labeling typically points out the exact counterion—mesylate—helping distinguish it from its chloride cousin. Storage instructions emphasize keeping DOTAP cool and desiccated, and rightfully so; anyone who’s seen what humidity does to cationic lipids understands how essential that is.
DOTAP Mesylate Salt synthesis follows a sequence that reflects both simplicity and high yield, starting with 1,2-dioleoyl-sn-glycerol, which reacts with a trimethylammonium functional group under carefully controlled conditions. The resultant lipid—initially the chloride version—then exchanges its anion for a mesylate via a simple counterion exchange in aqueous solution. Purification uses established protocols, such as precipitation or crystallization, followed by thorough checks using NMR or mass spectrometry. From my own benchwork, attention to detail during this purification step pays dividends in both reproducibility and downstream cell compatibility.
Once synthesized, DOTAP’s structure allows room for creative tweaks. Chemists often experiment with the lipid tails, replacing or lengthening them to adjust fusion capabilities or slow degradation inside the cell. Others attach targeting ligands directly onto the headgroup, steering DOTAP-based nanoparticles toward specific tissues, like tumors or inflamed regions. In some studies, researchers incorporate PEGylation to reduce immune system detection. Each of these modifications demands careful analysis—not just for improved performance, but for safety and enduring cell uptake as well.
DOTAP Mesylate Salt goes by a range of aliases in the literature and on product shelves. Some sources list it as 1,2-dioleoyl-3-trimethylammonium-propane mesylate; others just abbreviate to DOTAP mesylate. Researchers and suppliers sometimes refer to it more broadly as a cationic lipid transfection reagent—though that misses the elegance in its precise chemistry. Clarity in labeling here translates to smoother ordering, fewer mishaps, and better reproducibility in bioassays.
Working with cationic lipids demands attention to personal protection. DOTAP Mesylate, like other positively charged lipids, can disrupt mammalian membranes—not just those you’re experimenting with, but skin and eyes as well. Lab practice always includes gloves, lab coats, goggles, and effective fume hoods. Procedures stress minimizing inhalation, ingestion, or prolonged skin contact. Disposal sticks with biohazardous material routes, as lipid complexes with nucleic acids need thoughtful treatment. Adhering to these safety steps protects researchers and the work environment, and there’s no shortcut that works in the long run.
DOTAP Mesylate led the shift from viral to nonviral gene delivery. Biologists use it for transfection of mammalian cells, looking to express disease-related proteins, silence genes, or edit genomes. Pharmaceutical firms have begun scaling up DOTAP-based systems for vaccine delivery—seen most prominently in mRNA vaccine platforms. Emerging work applies DOTAP nanoparticles for CRISPR/Cas delivery, gene knockdown, and even immunotherapy. I’ve seen the growth of personalized medicine hinge in part on these lipid technologies, because DOTAP adapts quickly to new payloads and targets.
Today, lipid nanoparticle technology grabs headlines—often tracing back to relentless improvements in DOTAP formulations. Teams keep refining mixing ratios, adding co-lipids, or incorporating adjuvants to fine-tune DOTAP’s properties for different tissues. Studies on DOTAP stability, shelf-life, and scalability address a persistent bottleneck in translating lab ideas to clinical products. Some of the most promising research investigates combinatorial chemistry approaches, where libraries of analogs bring new efficiency, toxicity, or targeting profiles. As research funding grows for RNA therapeutics and gene editing, DOTAP remains a key ingredient in the race to treat rare and common diseases alike.
Questions around toxicity follow every new delivery system, and DOTAP is no exception. Decades of cell culture experiments reveal that high cationic lipid concentrations cause membrane disruption and trigger unwanted immune responses or cell death. In animals, DOTAP’s toxicity connects directly to dosage, route of administration, and formulation details. Research teams now run thorough cytotoxicity, immunogenicity, and genotoxicity screens before considering clinical steps. Approaches like blending DOTAP with neutral lipids or PEG derivatives have cut back on side effects. Yet, these precautions stem from practical experience—failures and successes alike. Rigorous preclinical data offers the only reliable roadmap to safe patient-facing applications.
The future for DOTAP Mesylate Salt and similar lipids looks filled with new opportunities and fresh challenges. As demand for RNA and gene delivery accelerates—COVID-19 vaccine development put a global spotlight on this—DOTAP formulations will keep moving beyond just basic research and into scalable, therapeutic-grade solutions. Continued innovation means new hybrid nanoparticles, smarter targeting mechanisms, and next-generation analogs that carry more therapeutic material with less collateral toxicity. It’s clear from recent research that DOTAP will play a central role in areas like personalized vaccines, regenerative medicine, and targeted gene correction. For the foreseeable future, the search continues for safer, more efficient cationic lipids, but DOTAP's legacy and adaptability give it staying power amid clinical translation efforts.
DOTAP Mesylate Salt steps onto the stage as a cationic lipid—simply, a fat-like molecule with a positive charge. For people outside the lab, that may not mean much, but in my time working alongside research teams, I’ve seen how this material opens doors in gene therapy and vaccine development. The positive charge on the DOTAP molecule rides side by side with DNA and RNA’s natural negative charge, helping scientists shuttle genetic material into living cells. Researchers aren’t looking for tricks; they want reliable ways to get genes where they need to go. DOTAP Mesylate Salt offers them one of the most direct delivery routes available.
The past several years brought lipid nanoparticles into everyday conversation due to COVID-19 vaccines. DOTAP became a team player in these new vaccines—especially those relying on RNA. People like me, involved in science outreach and education, often hear questions about the “ingredients” in vaccines. Most folks are surprised to learn that lipids such as DOTAP aren’t just passive ingredients; they’re essential couriers. In practical terms, DOTAP’s structure helps protect fragile RNA, carrying it past hungry enzymes and tough cell membranes right into the heart of cells, where the biological message can do its job.
Cancer therapy doesn’t always look like a pill or an IV drip. Over the last decade, researchers began pushing for more targeted approaches—putting the medicine right where it’s needed and nowhere else. Several labs I’ve spoken with use DOTAP-based nanoparticles to deliver siRNA and DNA directly into cancer cells. These particles seek out cancer cells using surface markers, and once they dock, DOTAP releases its genetic cargo. Results from early trials point to fewer side effects and promising efficacy in halting tumor growth.
Handling DOTAP Mesylate Salt isn’t all smooth sailing. The same positive charge that makes it such a good delivery vehicle can cause problems if researchers don’t tune the dose carefully. High concentrations sometimes irritate tissues or trigger unintended immune responses. Several scientists have recounted challenges during formulation, especially when moving from bench research to animal testing. Manufacturers have started offering more refined versions to reduce side effects, but close monitoring is part of every clinical step.
Researchers know that relying too heavily on a single ingredient—especially something as specialized as DOTAP Mesylate Salt—poses risks. Costs can spike due to supply shortages or complex manufacturing. To keep modern therapies widely available, teams across the globe are exploring new lipid combinations, biocompatible carriers, and scalable production methods. From my experience meeting with innovators in biotechnology, many believe future breakthroughs will emerge from combining the strengths of DOTAP with other emerging technologies, like biodegradable polymers and plant-derived lipids.
The story of DOTAP Mesylate Salt highlights a lesson for anyone following scientific progress: every advancement relies on gaining public trust and sharing clear, practical information. Community feedback and patient input play a decisive role in how products reach clinics. Whether working in the lab, teaching in classrooms, or talking with neighbors, the key is always the same—keeping the science open, honest, and accessible to all.
DOTAP Mesylate Salt, often used in gene delivery and transfection research, demands more attention than just stacking bottles on a shelf. This chemical’s quality and performance depend directly on how a lab handles storage. Many researchers, especially those early in their careers, learn quickly after finding a degraded vial that not all chemicals tolerate a standard room temperature space.
Anyone who’s unpacked DOTAP Mesylate knows the packaging usually hints at a preferred storage environment. Best practice calls for a refrigerator, with temperatures ranging between 2°C and 8°C. Consistent coolness slows down any breakdown of the salt. Moisture causes trouble, too. Labs in humid climates can’t ignore this, as unopened vials may start clumping or change texture over time, both bad news for experiments. Silica gel packets in the storage area can help, but the real defense comes from making sure the container seals tightly every time you use it.
There’s a reason that many chemical suppliers send sensitive materials in dark bottles. DOTAP Mesylate Salt isn’t fond of bright lights, especially direct sunlight. Exposure encourages chemical changes that lower its reliability in critical applications like liposome formation. My own lab once left a bottle on a sunny windowsill for a couple of hours and ended up wasting both expensive reagent and precious time. Shelves far away from windows or those UV-blocking cabinets provide the simplest fix.
Not every lab container counts as equal. DOTAP Mesylate Salt arrives in containers that aren’t just an afterthought. Manufacturers pick certain plastics or dark glass to prevent unwanted interactions. Never switch to a different bottle just because it’s convenient—chemicals can react with the wrong type of material, or leach out substances, messing with future experiments. Double-check labels and avoid makeshift solutions.
Forget vague notes. Accurate labeling tracks storage and avoids using an old stock that’s lost potency. List receiving dates and any times the salt spends out of the fridge. Some teams add log sheets for every vial to keep everyone accountable in busy shared spaces.
DOTAP Mesylate doesn’t play well with temperature swings. Repeated freeze-thaw cycles change its properties—think clumping, loss of activity, or separation. I ran into this once out of habit, thinking longer-term freezing would help. Instead, I ended up with a batch that refused to disperse properly in solution, wasting the entire set of planned experiments. Split stock into small aliquots, so only the required amount thaws at any time.
Labs short on refrigerator space or working in field conditions have invested in portable coolers with active temperature monitoring, reducing variability. Some institutions rotate stocks often and train new staff on the risks of storage shortcuts. Others have even switched to automated storage systems with barcoding, boosting both oversight and reliability. Digital temperature logs help flag mishaps quickly, protecting sample integrity.
DOTAP Mesylate Salt is no small financial investment. Poor storage wrecks research budgets and delays projects. Paying attention to temperature, humidity, light, and handling does more than reduce waste—it safeguards the science that depends on every batch.
Tinkering with transfection brings both excitement and a fair bit of frustration. Years back, my first trials with liposomal reagents showed me it's not just about dumping more compound into the dish. Strong signals can come at the price of stressed cells, so it pays to walk a careful line. DOTAP Mesylate Salt stands out because it encourages DNA to slip across cell membranes, but the quantity you mix in shapes almost everything about your experiment’s outcome.
Researchers stick to 1–10 μg/ml as a practical starting range for DOTAP Mesylate Salt transfections. A sweet spot often emerges right around 2–5 μg/ml for plasmid DNA. Too high, and you risk cytotoxicity—cells round up or float off, often in just a few hours. Too low, and you’ll miss the signal completely. The brand and batch matter, but proper pilot testing sometimes separates a clean experiment from a wasted afternoon.
A concentration between 1 and 10 μg/ml comes from years of cell biology and chemistry meeting on the lab bench. Cell culture isn’t forgiving when cationic lipids poke too many holes in the membrane. I’ve watched perfectly healthy HeLa or CHO cells go from happy to haggard after an overzealous hand on the pipette. What matters isn’t just the transfection efficiency charted in a glossy paper but the recovery and proliferation days after.
Several labs at leading institutions track post-transfection cell health closely. Work with DOTAP at about 2.5 μg/ml yields reliable expression in HEK293 cells, a trusty favorite. Push much past 5 μg/ml, and even robust lines like HEK293 start losing their edge. At the same time, some trickier cells, primary neurons or stem cells, get fussy, requiring a lighter touch. Sometimes you tweak not only the lipid but also the ratio of DNA-to-lipid, sometimes running 1:1, other times a little heavier on the DNA depending on results.
Knockdown, overexpression, CRISPR—your aim shapes a lot about transfection. For simple overexpression, a mid-range DOTAP dose usually does the trick. For genome editing, you measure effects for weeks, not just hours, so you give extra thought to minimizing cell death and genotoxicity. Published studies in journals like “Nature Methods” and guidance from suppliers such as Sigma-Aldrich often reinforce this approach, but hands-on experience still trumps factory protocols.
Optimizing the concentration means running a matrix—varying DOTAP and DNA doses side by side with cell viability stains. Total DNA shouldn’t always scale with surface area, since different plates soak up lipid at different rates. Serum in the medium can block transfection but keeps cells alive, so you find the right balance by skipping serum for a few hours, then adding it back in later.
Sterile technique, fresh media, and gentler mixing guard against batch-to-batch surprises. In busy academic labs and biotech startups alike, people share that dot of wisdom on sticky notes: “Try 2.5 μg/ml, but watch the cells.” Savvy researchers repeat this dose-finding step whenever starting with a new cell line.
Perfecting DOTAP Mesylate Salt concentration isn’t a one-time fix. Tuning conditions rewards patient trial and error. The right dose protects your research budget and the well-being of cultures—both personal and cellular—across the lab.
Scientists working with gene delivery, vaccine adjuvants, or RNA therapeutics keep looking for lipid-based compounds that mix safety and performance. DOTAP Mesylate Salt often crops up during lab meetings when teams brainstorm non-viral delivery options, especially for nucleic acids. It stands out as a cationic lipid with a reputation for forming strong complexes with DNA and RNA. This bonding helps ferry these molecules through the usually impenetrable cell membrane walls.
Not every material that works in a test tube transfers to animals or humans without problems. Many times, substances that spark hope during small-scale pilot studies cause headaches during preclinical testing, with inflammation, liver issues, or immune responses that nobody wants to see. This is where DOTAP Mesylate Salt keeps surfacing in debates: Can it hold up under the stress of an actual living system?
Every time our team tested DOTAP-based formulations in cell cultures, delivery worked much better versus plain buffer or naked DNA. It made a real difference for hard-to-transfect lines. Once studies moved to small animals, dose levels and administration route started to matter a great deal. The salt form, mesylate, usually dissolves more cleanly and stays stable, avoiding some aggregation headaches seen with other forms.
Animal trials gave mixed results. Some teams saw mild stress responses at higher lipid doses, but no full-blown toxicity below certain thresholds. Our collaborations with immunology groups kept a close eye on cytokine profiles and organ responses after treatment; the outcomes leaned more toward mild, manageable effects at moderate dosing.
Relevant publications (see Nature Communications, 2023) back up personal experience. Data suggests that DOTAP, especially as its mesylate salt, tends to clear out of animal systems quickly. It does not bioaccumulate in the way that some polymer carriers or other cationic lipids do. Scientists in clinical research flag faster clearance as a good sign.
At higher concentrations or repeated dosing, DOTAP Mesylate Salt sometimes sparks mild immune reactions. Some labs saw mild spleen or liver stress outside ideal dosage windows. This did not match the damaging immune storms seen with some less-refined lipids. Pharmacokinetic findings from well-run studies painted the same picture: moderate doses every few weeks could minimize side effects, often without knocking out delivery performance.
Plenty of experts argue about the role of formulation. Encapsulating DOTAP mesylate with PEG or using it in combination with cholesterol tweaks its in vivo behavior. First-hand dosing in mouse models confirmed softer immune signatures using these tricks. Finding the sweet spot—a balance of payload delivery with controllable safety—remains the name of the game. Experience from RNA vaccine prototypes and tumor therapy models suggests that formulation choices can tip the scale from tolerable to problematic.
Researchers trying to improve DOTAP Mesylate Salt’s safety profile focus on smarter delivery strategies. Careful control of particle size, surface charge, and co-lipid content already extend its safety margins. Ongoing updates come from direct clinical trial feedback, not just data sheets or supplier notes. Labs that put in time for rigorous lot-to-lot testing with in vivo dosing do better in spotting rare adverse reactions or drift in behavior due to manufacturing differences.
DOTAP Mesylate Salt won’t fit every use case, but careful formulation and dosing plans keep it in the conversation for gene therapy and RNA delivery. The path forward keeps demanding open communication across pharmaceutical science, toxicology, and clinical trial teams.
DOTAP Mesylate Salt usually shows up as a white, powdery substance. In my experience, the first question folks have is how to handle this powder to get consistent and reliable results in gene delivery or cell transfection experiments. Before jumping to mixing or dissolving, it pays to take a close look at purity. Certificates of Analysis from suppliers give you some idea, but verifying with a little TLC plate or mass spec never hurts. Quality at this basic step goes a long way.
DOTAP doesn’t dissolve in water on its own. Most labs prefer working with chloroform, methanol, or a mix of both. I usually weigh the salt on a precision balance — a stable, vibration-free spot matters, since static from DOTAP powder will send it flying. Always work glove-up in a ventilated hood.
Adding the right volume of a pure solvent straight to the powder, swirl gently—never shake too hard or you end up with annoying bubbles. Think patience, not force. Once you’ve got a clear solution, it’s common to use a glass syringe fitted with a nylon or PTFE filter (0.22 microns works for most protocols). Filtering like this prevents particles that mess up downstream work.
DOTAP’s not invincible—light and air speed up its breakdown, and those breakdown products lead to unreliable experiment results. The best move after filtering is to split your solution into amber glass vials, seal them tight, and label everything with date, concentration, and solvent. Most protocols call for storing at -20°C. In my lab, I always keep one vial in the working fridge, with the backup stock untouched in the deep freeze. Thawing and freezing the same vial too many times just invites trouble; small aliquots work better.
Every batch can behave a little differently, so I don’t trust the numbers from the bottle alone. Before using DOTAP with cells, I double-check concentration by measuring the absorbance at the right wavelength—usually around 207 or 260 nm, depending on the solvent. Some protocols call for drying down the solvent under nitrogen before hydration in buffer, especially if planning to encapsulate DNA or RNA. Drying under nitrogen gas leaves a thin film at the bottom of your round-bottom flask, and hydrating with a warm buffer, swirling gently, gives small, uniform liposomes.
I’ve seen teams cut corners by skipping the filtering or working on open benches, and control cells start acting weird. Even small amounts of contamination can ruin months of work, not to mention waste precious DNA or RNA cargo. Those frustrated moments push everyone to get more detailed and careful, not less.
Some labs switch to using ethanol instead of chloroform to improve cell compatibility. Others buy pre-dissolved DOTAP, though it costs more and shelf life can suffer. Setting up a regular schedule for checking old stocks—monthly works for us—stops nasty surprises before key experiments. Using the same protocol each time, with fresh tips and glassware rinsed in solvent, brings actual scientific control into the workflow. If you’re new to this, talking to colleagues helps, but running your own control experiments teaches you far more about how these preparations work—or don’t.
| Names | |
| Preferred IUPAC name | 2,3-bis[(Z)-octadec-9-enoyloxy]propyl(trimethyl)azanium methanesulfonate |
| Other names |
1,2-Dioleoyl-3-trimethylammonium-propane methanesulfonate DOTAP mesylate 1,2-Dioleoyl-3-trimethylammonium-propane methanesulfonate salt N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium, mesylate |
| Pronunciation | /ˈwaɪ.tuː daɪˌoʊliˌoʊɪl θriː traɪˌmiːθəlˌæməˌniəm prəˈpeɪn ˈmes.ɪ.leɪt sɔːlt/ |
| Identifiers | |
| CAS Number | 155160-43-5 |
| Beilstein Reference | 4127241 |
| ChEBI | CHEBI:133105 |
| ChEMBL | CHEMBL3983489 |
| ChemSpider | 27923505 |
| DrugBank | DB11397 |
| ECHA InfoCard | 17f070d3-4d7e-4acd-a8b2-2bbf470901df |
| EC Number | 9002-83-9 |
| Gmelin Reference | 2633938 |
| KEGG | C13361 |
| MeSH | D076454 |
| PubChem CID | 135409504 |
| RTECS number | WA2625000 |
| UNII | 5Q0S90GAJ6 |
| UN number | Not regulated |
| Properties | |
| Chemical formula | C44H88NO5S |
| Molar mass | 698.6 g/mol |
| Appearance | White solid |
| Density | 0.98 g/mL |
| Solubility in water | Soluble in water |
| log P | 4.43 |
| Vapor pressure | Negligible |
| Basicity (pKb) | pKb ~ 4.3 |
| Refractive index (nD) | 1.465 |
| Viscosity | Viscous oil |
| Dipole moment | 20.3944 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 1475.6 J/mol·K |
| Pharmacology | |
| ATC code | |
| Hazards | |
| Main hazards | May cause skin and eye irritation. |
| GHS labelling | **"GHS07, Exclamation mark, Warning, H315, H319, H335"** |
| Pictograms | ``` GHS07 ``` |
| Signal word | Danger |
| Hazard statements | Hazard statements: Causes skin irritation. Causes serious eye irritation. |
| Precautionary statements | Precautionary statements: P264, P280, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: |
| Flash point | >100°C |
| LD50 (median dose) | LD50 (median dose): >2000 mg/kg (rat, oral) |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP) Mesylate Salt: Not established |
| REL (Recommended) | ≤0.5 mg/mL |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
DOTAP chloride DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) DPTAP (1,2-dipalmitoyl-3-trimethylammonium-propane) DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) DOTMA (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride) |
